Review



ct26 murine colon carcinoma cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC ct26 murine colon carcinoma cells
    Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting <t>CT26</t> murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.
    Ct26 Murine Colon Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 3500 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 murine colon carcinoma cells/product/ATCC
    Average 99 stars, based on 3500 article reviews
    ct26 murine colon carcinoma cells - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Recombinant CALR polarizes and activates macrophages in tumors"

    Article Title: Recombinant CALR polarizes and activates macrophages in tumors

    Journal: Molecular Therapy Oncology

    doi: 10.1016/j.omton.2025.201121

    Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting CT26 murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.
    Figure Legend Snippet: Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting CT26 murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

    Techniques Used: Recombinant, Activation Assay, Injection, Saline, Control, Expressing, Bacteria

    Recombinant CALR increases helper T cell activity in tumors (A) The extent of T cell infiltration was determined in mice (see ) with CT26 tumors that were intratumorally injected (on days 0, 3, and 6) with saline (PBS), bacterial control lysate (BC), or lysate from CALR-expressing bacteria (CALR). On day 9, injection of CALR lysate significantly increased the number of T cells in tumors (per 10,000 cells analyzed) compared to saline controls ( p = 0.0495). (B) The percentage of helper T cells per 10,000 cells analyzed. (C) On day 9, injection with CALR lysate significantly increased the number of activated helper T cells (per 10,000 cells analyzed) in tumors compared to saline controls ( p = 0.0067). Data are represented as mean ± SEM. The statistical comparisons in (A–C) are ANOVA followed by Dunnett’s test. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.
    Figure Legend Snippet: Recombinant CALR increases helper T cell activity in tumors (A) The extent of T cell infiltration was determined in mice (see ) with CT26 tumors that were intratumorally injected (on days 0, 3, and 6) with saline (PBS), bacterial control lysate (BC), or lysate from CALR-expressing bacteria (CALR). On day 9, injection of CALR lysate significantly increased the number of T cells in tumors (per 10,000 cells analyzed) compared to saline controls ( p = 0.0495). (B) The percentage of helper T cells per 10,000 cells analyzed. (C) On day 9, injection with CALR lysate significantly increased the number of activated helper T cells (per 10,000 cells analyzed) in tumors compared to saline controls ( p = 0.0067). Data are represented as mean ± SEM. The statistical comparisons in (A–C) are ANOVA followed by Dunnett’s test. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

    Techniques Used: Recombinant, Activity Assay, Injection, Saline, Control, Expressing, Bacteria



    Similar Products

    99
    ATCC ct26 murine colon carcinoma cells
    Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting <t>CT26</t> murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.
    Ct26 Murine Colon Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 murine colon carcinoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 murine colon carcinoma cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC ct26 murine colorectal carcinoma cell line
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Murine Colorectal Carcinoma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 murine colorectal carcinoma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 murine colorectal carcinoma cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    crl  (ATCC)
    99
    ATCC crl
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Crl, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/crl/product/ATCC
    Average 99 stars, based on 1 article reviews
    crl - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    ct26  (ATCC)
    99
    ATCC ct26
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC ct26 mouse colorectal carcinoma
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Mouse Colorectal Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 mouse colorectal carcinoma/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 mouse colorectal carcinoma - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC ct26 colorectal carcinoma cells
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Ct26 Colorectal Carcinoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 colorectal carcinoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 colorectal carcinoma cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC murine colon carcinoma cell lines
    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with <t>CT26</t> on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.
    Murine Colon Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine colon carcinoma cell lines/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine colon carcinoma cell lines - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC ct26 colon cancer cells
    EA restores reduced adipocyte function in CM‐stimulated white adipocytes. (A) The experimental scheme for the preparation of the <t>CT26</t> CM is shown. (B) IL‐6 levels were measured in CT26 CM with ELISA kits ( n = 3). (C) Intracellular lipid droplets were stained with Oil Red O (magnification 400×, scale bar 75 = μm). (D) The quantification of intracellular lipid was detected at 500 nm in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (3.1, 6.3 and 12.5 μM) ( n = 3). (E) The levels of intracellular and extracellular free fatty acids were measured in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (6.3 and 12.5 μM) ( n = 3). (F, G) The expression of adipokines was analysed using a Mouse Adipokine Proteome Array kit. (H) The protein expression of IGFBP‐3 and lipocalin‐2 was analysed with ImageJ ( n = 2). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 or **** p < 0.0001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.
    Ct26 Colon Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/ct26 colon cancer cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    ct26 colon cancer cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC 105 ct26 colon cancer cells
    EA restores reduced adipocyte function in CM‐stimulated white adipocytes. (A) The experimental scheme for the preparation of the <t>CT26</t> CM is shown. (B) IL‐6 levels were measured in CT26 CM with ELISA kits ( n = 3). (C) Intracellular lipid droplets were stained with Oil Red O (magnification 400×, scale bar 75 = μm). (D) The quantification of intracellular lipid was detected at 500 nm in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (3.1, 6.3 and 12.5 μM) ( n = 3). (E) The levels of intracellular and extracellular free fatty acids were measured in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (6.3 and 12.5 μM) ( n = 3). (F, G) The expression of adipokines was analysed using a Mouse Adipokine Proteome Array kit. (H) The protein expression of IGFBP‐3 and lipocalin‐2 was analysed with ImageJ ( n = 2). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 or **** p < 0.0001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.
    105 Ct26 Colon Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/105 ct26 colon cancer cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    105 ct26 colon cancer cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC murine colon adenocarcinoma ct26
    EA restores reduced adipocyte function in CM‐stimulated white adipocytes. (A) The experimental scheme for the preparation of the <t>CT26</t> CM is shown. (B) IL‐6 levels were measured in CT26 CM with ELISA kits ( n = 3). (C) Intracellular lipid droplets were stained with Oil Red O (magnification 400×, scale bar 75 = μm). (D) The quantification of intracellular lipid was detected at 500 nm in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (3.1, 6.3 and 12.5 μM) ( n = 3). (E) The levels of intracellular and extracellular free fatty acids were measured in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (6.3 and 12.5 μM) ( n = 3). (F, G) The expression of adipokines was analysed using a Mouse Adipokine Proteome Array kit. (H) The protein expression of IGFBP‐3 and lipocalin‐2 was analysed with ImageJ ( n = 2). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 or **** p < 0.0001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.
    Murine Colon Adenocarcinoma Ct26, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine colon adenocarcinoma ct26/product/ATCC
    Average 99 stars, based on 1 article reviews
    murine colon adenocarcinoma ct26 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting CT26 murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

    Journal: Molecular Therapy Oncology

    Article Title: Recombinant CALR polarizes and activates macrophages in tumors

    doi: 10.1016/j.omton.2025.201121

    Figure Lengend Snippet: Recombinant CALR reduces tumor growth and increases M1 macrophages (A) To measure the effect on tumor growth and immune cell activation, bacterial lysate was injected into tumor-bearing mice. Tumors were formed by subcutaneously injecting CT26 murine colon carcinoma cells into the flank of BALB/c mice. After 2 weeks, the mice were injected intratumorally with saline, bacterial control lysate, or lysate from CALR-expressing bacteria. One set of mice received injections at days 0, 3, and 6; were monitored for tumor growth; and their tumors were harvested at day 9 for analysis of immune cells. A second set of mice received only one injection at day 0, and tumors were harvested at day 3 for analysis. (B) Intratumoral injection of CALR lysate decreased tumor growth compared to saline controls ( p = 0.0089). Bacterial control lysate also reduced tumor growth compared to controls ( p = 0.0204). Volumes are reported relative to those on day 0. (C–F) On day 3, recombinant CALR did not affect (C) the number of leukocytes, (D) the number of M1 macrophages (per 10,000 cells analyzed), or the number of M1 macrophages expressing either (E) CD80 or (F) CD86 (per 10,000 cells analyzed) in tumors. (G) On day 9, injection with CALR lysate significantly increased the number of leukocytes in tumors compared to saline controls ( p = 0.0042). (H) On day 9, CALR lysate also significantly increased the number of M1 macrophages in tumors compared to bacterial controls ( p = 0.0480) and saline ( p = 0.0061). (I) CALR lysate significantly increased the number of M1 macrophages expressing CD80 (per 10,000 cells analyzed) compared to saline controls ( p = 0.0063). (J) CALR lysate also increased the number of M1 macrophages expressing CD86 (per 10,000 cells analyzed) compared to bacterial controls ( p = 0.0445) and saline ( p = 0.0077). Data are represented as mean ± SEM. The statistical comparisons in (B) are two-way ANOVA followed by Tukey’s method. The statistical comparisons in (C–J) are ANOVA followed by Tukey’s method. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

    Article Snippet: JAWSII murine dendritic cells and CT26 murine colon carcinoma cells were obtained from ATCC, confirmed by STR profiling by Charles River Research Animal Diagnostic Services, and passaged for fewer than 6 months.

    Techniques: Recombinant, Activation Assay, Injection, Saline, Control, Expressing, Bacteria

    Recombinant CALR increases helper T cell activity in tumors (A) The extent of T cell infiltration was determined in mice (see ) with CT26 tumors that were intratumorally injected (on days 0, 3, and 6) with saline (PBS), bacterial control lysate (BC), or lysate from CALR-expressing bacteria (CALR). On day 9, injection of CALR lysate significantly increased the number of T cells in tumors (per 10,000 cells analyzed) compared to saline controls ( p = 0.0495). (B) The percentage of helper T cells per 10,000 cells analyzed. (C) On day 9, injection with CALR lysate significantly increased the number of activated helper T cells (per 10,000 cells analyzed) in tumors compared to saline controls ( p = 0.0067). Data are represented as mean ± SEM. The statistical comparisons in (A–C) are ANOVA followed by Dunnett’s test. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

    Journal: Molecular Therapy Oncology

    Article Title: Recombinant CALR polarizes and activates macrophages in tumors

    doi: 10.1016/j.omton.2025.201121

    Figure Lengend Snippet: Recombinant CALR increases helper T cell activity in tumors (A) The extent of T cell infiltration was determined in mice (see ) with CT26 tumors that were intratumorally injected (on days 0, 3, and 6) with saline (PBS), bacterial control lysate (BC), or lysate from CALR-expressing bacteria (CALR). On day 9, injection of CALR lysate significantly increased the number of T cells in tumors (per 10,000 cells analyzed) compared to saline controls ( p = 0.0495). (B) The percentage of helper T cells per 10,000 cells analyzed. (C) On day 9, injection with CALR lysate significantly increased the number of activated helper T cells (per 10,000 cells analyzed) in tumors compared to saline controls ( p = 0.0067). Data are represented as mean ± SEM. The statistical comparisons in (A–C) are ANOVA followed by Dunnett’s test. Asterisks indicate significance: ∗ p < 0.05; ∗∗ p < 0.01.

    Article Snippet: JAWSII murine dendritic cells and CT26 murine colon carcinoma cells were obtained from ATCC, confirmed by STR profiling by Charles River Research Animal Diagnostic Services, and passaged for fewer than 6 months.

    Techniques: Recombinant, Activity Assay, Injection, Saline, Control, Expressing, Bacteria

    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Journal: iScience

    Article Title: Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination

    doi: 10.1016/j.isci.2025.114572

    Figure Lengend Snippet: Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Article Snippet: The CT26 murine colorectal carcinoma cell line was purchased from ATCC (CRL-2638).

    Techniques: Irradiation, Injection

    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Journal: iScience

    Article Title: Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination

    doi: 10.1016/j.isci.2025.114572

    Figure Lengend Snippet: Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Article Snippet: No additional authentication was performed beyond obtaining MC38, Moc1, and Moc2 from collaborating laboratories that routinely use and maintain these models, and CT26 from ATCC.

    Techniques: Irradiation, Injection

    Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Journal: iScience

    Article Title: Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination

    doi: 10.1016/j.isci.2025.114572

    Figure Lengend Snippet: Combination RT and anti-CCR8 reduces tumor burden and improve survival in distant non-irradiated tumors BALB/c mice were injected with CT26 on both flanks. Tumor-bearing mice were treated with a “pre” treatment strategy. Mice were injected i.p. with anti-CCR8 on days 7, 10, and 14 and treated with 12 Gy RT to the right flank tumor (treated) on day14 post-tumor inoculation. The left tumor (untreated) did not receive RT. Tumor growth and survival were assessed. A total of 8 mice were analyzed per group. Data are represented as mean ± SD. Statistics for survival plots were performed using a Mantel-Cox test between groups. ns = not significant, ∗∗∗∗ p < 0.0001, ∗∗∗ p < 0.001, ∗∗ p < 0.01, ∗ p < 0.05.

    Article Snippet: CT26 mouse colorectal carcinoma , ATCC , Cat #: CRL-2638.

    Techniques: Irradiation, Injection

    EA restores reduced adipocyte function in CM‐stimulated white adipocytes. (A) The experimental scheme for the preparation of the CT26 CM is shown. (B) IL‐6 levels were measured in CT26 CM with ELISA kits ( n = 3). (C) Intracellular lipid droplets were stained with Oil Red O (magnification 400×, scale bar 75 = μm). (D) The quantification of intracellular lipid was detected at 500 nm in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (3.1, 6.3 and 12.5 μM) ( n = 3). (E) The levels of intracellular and extracellular free fatty acids were measured in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (6.3 and 12.5 μM) ( n = 3). (F, G) The expression of adipokines was analysed using a Mouse Adipokine Proteome Array kit. (H) The protein expression of IGFBP‐3 and lipocalin‐2 was analysed with ImageJ ( n = 2). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 or **** p < 0.0001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.

    Journal: Journal of Cachexia, Sarcopenia and Muscle

    Article Title: Ellagic Acid Alleviates Abnormal Fat Reduction by Activating the RXRβ–PPARγ Pathways in a CT26 Tumour‐Induced Cachexia Mouse Model

    doi: 10.1002/jcsm.70176

    Figure Lengend Snippet: EA restores reduced adipocyte function in CM‐stimulated white adipocytes. (A) The experimental scheme for the preparation of the CT26 CM is shown. (B) IL‐6 levels were measured in CT26 CM with ELISA kits ( n = 3). (C) Intracellular lipid droplets were stained with Oil Red O (magnification 400×, scale bar 75 = μm). (D) The quantification of intracellular lipid was detected at 500 nm in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (3.1, 6.3 and 12.5 μM) ( n = 3). (E) The levels of intracellular and extracellular free fatty acids were measured in 3T3‐L1 cells differentiated into white adipocytes, and treated with 50% of CT26 CM or EA (6.3 and 12.5 μM) ( n = 3). (F, G) The expression of adipokines was analysed using a Mouse Adipokine Proteome Array kit. (H) The protein expression of IGFBP‐3 and lipocalin‐2 was analysed with ImageJ ( n = 2). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01, *** p < 0.001 or **** p < 0.0001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.

    Article Snippet: Briefly, all mice were first randomized by body weight and divided into a non‐tumour‐bearing vehicle group, which received a subcutaneous injection of PBS, and a tumour‐induction group, which was injected with 5 × 10 5 CT26 colon cancer cells (CRL‐2638, ATCC, Rockville, MD, USA).

    Techniques: Enzyme-linked Immunosorbent Assay, Staining, Expressing

    EA‐mediated RXRβ‐PPARγ axis activation mitigates the reduction of adipogenesis by CT26 CM. (A) Overview of the crystal structure of the complex between RXRB (PDB ID: 7A78) and EA, and expected intermolecular interactions are shown. (B) Relative mRNA expression of Rxrb was measured by RT‐PCR in 3T3‐L1 differentiated into white adipocytes with or without si Rxrb , and data are normalized to Gapdh ( n = 3). (C) Representative morphological images of 3T3‐L1 treated with siRxrb and/or EA are shown (magnification 400×, scale bar = 75 μm). (D) The lipid droplets were stained with BODIPY‐Green (magnification 1000×, scale bar = 25 μm). Lipid droplet sizes and area were measured using the ImageJ software ( n = 3). (E) Protein expression of PPARγ and ACC was measured by Western blot analysis. (F) Intensities of the protein bands were measured with ImageJ and normalized to β‐actin ( n = 6). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons and the non‐parametric Mann–Whitney U test for two‐group comparisons. * p < 0.05, ** p < 0.01 or *** p < 0.001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.

    Journal: Journal of Cachexia, Sarcopenia and Muscle

    Article Title: Ellagic Acid Alleviates Abnormal Fat Reduction by Activating the RXRβ–PPARγ Pathways in a CT26 Tumour‐Induced Cachexia Mouse Model

    doi: 10.1002/jcsm.70176

    Figure Lengend Snippet: EA‐mediated RXRβ‐PPARγ axis activation mitigates the reduction of adipogenesis by CT26 CM. (A) Overview of the crystal structure of the complex between RXRB (PDB ID: 7A78) and EA, and expected intermolecular interactions are shown. (B) Relative mRNA expression of Rxrb was measured by RT‐PCR in 3T3‐L1 differentiated into white adipocytes with or without si Rxrb , and data are normalized to Gapdh ( n = 3). (C) Representative morphological images of 3T3‐L1 treated with siRxrb and/or EA are shown (magnification 400×, scale bar = 75 μm). (D) The lipid droplets were stained with BODIPY‐Green (magnification 1000×, scale bar = 25 μm). Lipid droplet sizes and area were measured using the ImageJ software ( n = 3). (E) Protein expression of PPARγ and ACC was measured by Western blot analysis. (F) Intensities of the protein bands were measured with ImageJ and normalized to β‐actin ( n = 6). All data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons and the non‐parametric Mann–Whitney U test for two‐group comparisons. * p < 0.05, ** p < 0.01 or *** p < 0.001 were considered statistically significant. CM, conditioned medium. DM (Wh), differentiation medium. EA, ellagic acid.

    Article Snippet: Briefly, all mice were first randomized by body weight and divided into a non‐tumour‐bearing vehicle group, which received a subcutaneous injection of PBS, and a tumour‐induction group, which was injected with 5 × 10 5 CT26 colon cancer cells (CRL‐2638, ATCC, Rockville, MD, USA).

    Techniques: Activation Assay, Expressing, Reverse Transcription Polymerase Chain Reaction, Staining, Software, Western Blot, MANN-WHITNEY

    EA protects against body weight loss in CT26 tumour‐induced cachectic mice. (A) The experimental scheme of the in vivo study is shown. BALB/c mice were subcutaneously inoculated with 5 × 10 5 CT26 cells (CT26 group), except for the vehicle group. EA administration (10 mg/kg) via oral gavage was started 1 week after tumour cell injection (CT26 + EA group). 0.9% Normal saline (vehicle group and CT26 group) or EA (CT26 + EA group) was fed five times per week for 2 weeks. (B) The tumour‐free weight was calculated by subtracting the isolated tumour weight from the body weight ( n = 4). (C) The combined bilateral weight of the iWAT is shown ( n = 4). (D) The H&E‐stained image of the iWAT (magnification 400×, scale bar = 75 μm) is shown, and lipid droplet sizes were calculated using the ImageJ software. (E) The protein levels of C/EBPα, PPARγ, and pACC and ACC were analysed by Western blot analysis. Signal intensities of the protein bands were measured with ImageJ and normalized to β‐actin ( n = 4). (F) The paraffin‐embedded iWAT was stained with SREBP1 (green) and DAPI (blue) (magnification 1000×, scale bar = 25 μm), and representative images are shown. Fluorescence intensity of SREBP1 was quantified using the ImageJ software ( n = 4). Data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01 or *** p < 0.001 were considered statistically significant. EA, ellagic acid. eWAT, epididymal white adipose tissue. iWAT, inguinal white adipose tissue.

    Journal: Journal of Cachexia, Sarcopenia and Muscle

    Article Title: Ellagic Acid Alleviates Abnormal Fat Reduction by Activating the RXRβ–PPARγ Pathways in a CT26 Tumour‐Induced Cachexia Mouse Model

    doi: 10.1002/jcsm.70176

    Figure Lengend Snippet: EA protects against body weight loss in CT26 tumour‐induced cachectic mice. (A) The experimental scheme of the in vivo study is shown. BALB/c mice were subcutaneously inoculated with 5 × 10 5 CT26 cells (CT26 group), except for the vehicle group. EA administration (10 mg/kg) via oral gavage was started 1 week after tumour cell injection (CT26 + EA group). 0.9% Normal saline (vehicle group and CT26 group) or EA (CT26 + EA group) was fed five times per week for 2 weeks. (B) The tumour‐free weight was calculated by subtracting the isolated tumour weight from the body weight ( n = 4). (C) The combined bilateral weight of the iWAT is shown ( n = 4). (D) The H&E‐stained image of the iWAT (magnification 400×, scale bar = 75 μm) is shown, and lipid droplet sizes were calculated using the ImageJ software. (E) The protein levels of C/EBPα, PPARγ, and pACC and ACC were analysed by Western blot analysis. Signal intensities of the protein bands were measured with ImageJ and normalized to β‐actin ( n = 4). (F) The paraffin‐embedded iWAT was stained with SREBP1 (green) and DAPI (blue) (magnification 1000×, scale bar = 25 μm), and representative images are shown. Fluorescence intensity of SREBP1 was quantified using the ImageJ software ( n = 4). Data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01 or *** p < 0.001 were considered statistically significant. EA, ellagic acid. eWAT, epididymal white adipose tissue. iWAT, inguinal white adipose tissue.

    Article Snippet: Briefly, all mice were first randomized by body weight and divided into a non‐tumour‐bearing vehicle group, which received a subcutaneous injection of PBS, and a tumour‐induction group, which was injected with 5 × 10 5 CT26 colon cancer cells (CRL‐2638, ATCC, Rockville, MD, USA).

    Techniques: In Vivo, Injection, Saline, Isolation, Staining, Software, Western Blot, Fluorescence

    EA increases the expression of RXRβ in the iWAT of the CT26 cachexia model. (A) The tumour‐free weight was measured ( n = 7), and the percentage of fat in the total body was measured with DEXA analysis ( n = 3). (B) The combined bilateral weight of the iWAT and eWAT is shown ( n = 7). (C) The combined bilateral weight of TA was measured, and grip strength was measured ( n = 6–7). (D) The paraffin‐embedded iWAT was stained with RXRβ (green) and DAPI (blue) (magnification 1000×, scale bar = 25 μm), and representative images are shown. The bottom panels show zoomed views of the boxed areas in the top panels. (E) Index of correlation (IC) between RXRβ and nuclear (DAPI) was measured with the Colocalization Colormap plugin using ImageJ ( n = 4). (F) Schematic of the experimental models and the mechanism of action for EA. Data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01 or *** p < 0.001 were considered statistically significant. EA, ellagic acid. eWAT, epididymal white adipose tissue. iWAT, inguinal white adipose tissue.

    Journal: Journal of Cachexia, Sarcopenia and Muscle

    Article Title: Ellagic Acid Alleviates Abnormal Fat Reduction by Activating the RXRβ–PPARγ Pathways in a CT26 Tumour‐Induced Cachexia Mouse Model

    doi: 10.1002/jcsm.70176

    Figure Lengend Snippet: EA increases the expression of RXRβ in the iWAT of the CT26 cachexia model. (A) The tumour‐free weight was measured ( n = 7), and the percentage of fat in the total body was measured with DEXA analysis ( n = 3). (B) The combined bilateral weight of the iWAT and eWAT is shown ( n = 7). (C) The combined bilateral weight of TA was measured, and grip strength was measured ( n = 6–7). (D) The paraffin‐embedded iWAT was stained with RXRβ (green) and DAPI (blue) (magnification 1000×, scale bar = 25 μm), and representative images are shown. The bottom panels show zoomed views of the boxed areas in the top panels. (E) Index of correlation (IC) between RXRβ and nuclear (DAPI) was measured with the Colocalization Colormap plugin using ImageJ ( n = 4). (F) Schematic of the experimental models and the mechanism of action for EA. Data are expressed as the mean ± SEM. Statistical significance was determined using a one‐way ANOVA with Tukey's post hoc test for multigroup comparisons. * p < 0.05, ** p < 0.01 or *** p < 0.001 were considered statistically significant. EA, ellagic acid. eWAT, epididymal white adipose tissue. iWAT, inguinal white adipose tissue.

    Article Snippet: Briefly, all mice were first randomized by body weight and divided into a non‐tumour‐bearing vehicle group, which received a subcutaneous injection of PBS, and a tumour‐induction group, which was injected with 5 × 10 5 CT26 colon cancer cells (CRL‐2638, ATCC, Rockville, MD, USA).

    Techniques: Expressing, Staining